September 4, 2018 09:47 AM EDT

Brainstorm recruits Novartis vet Araya as chief commercial officer; Roche out-licenses IPF drug to Shanghai's Ark

John Carroll

Editor & Founder

→ BrainStorm Cell Therapeutics $BCLI has appointed Novartis vet Arturo Araya as chief commercial officer. Araya had been global head of commercial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Brainstorm recruits Novartis vet Araya as chief commercial officer; Roche out-licenses IPF drug to Shanghai's Ark

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

CMS explains what went into its first round of drug price negotiations

Brain­storm re­cruits No­var­tis vet Araya as chief com­mer­cial of­fi­cer; Roche out-li­cens­es IPF drug to Shang­hai's Ark

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Brainstorm recruits Novartis vet Araya as chief commercial officer; Roche out-licenses IPF drug to Shanghai's Ark

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

CMS explains what went into its first round of drug price negotiations